Neuroone Medical Technologies is trading at $1.68, down 5.04%, after falling from the August 28 close of $1.77; no clear company-specific catalyst was identified for August 31, 2026.

  • Latest disclosed event: successful completion of three large-animal StereoCED procedures on August 27.
  • That development was positive, rather than an apparent negative trigger.
  • Broader equities are modestly weaker, but market direction alone appears insufficient to explain the decline.